These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 20812891)

  • 1. Emerging Bcl-2 inhibitors for the treatment of cancer.
    Azmi AS; Wang Z; Philip PA; Mohammad RM; Sarkar FH
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):59-70. PubMed ID: 20812891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 inhibitors: emerging drugs in cancer therapy.
    Bodur C; Basaga H
    Curr Med Chem; 2012; 19(12):1804-20. PubMed ID: 22414090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.
    Bajwa N; Liao C; Nikolovska-Coleska Z
    Expert Opin Ther Pat; 2012 Jan; 22(1):37-55. PubMed ID: 22195752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting apoptosis pathways for new cancer therapeutics.
    Bai L; Wang S
    Annu Rev Med; 2014; 65():139-55. PubMed ID: 24188661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
    Suvarna V; Singh V; Murahari M
    Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective targeting of antiapoptotic BCL-2 proteins in cancer.
    Timucin AC; Basaga H; Kutuk O
    Med Res Rev; 2019 Jan; 39(1):146-175. PubMed ID: 29846950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic inhibition of BCL-2 and related family members.
    Levy MA; Claxton DF
    Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.
    Opferman JT
    FEBS J; 2016 Jul; 283(14):2661-75. PubMed ID: 26293580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
    Yap JL; Chen L; Lanning ME; Fletcher S
    J Med Chem; 2017 Feb; 60(3):821-838. PubMed ID: 27749061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
    Sarosiek KA; Letai A
    FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Bcl-2 family for cancer therapy.
    Thomas S; Quinn BA; Das SK; Dash R; Emdad L; Dasgupta S; Wang XY; Dent P; Reed JC; Pellecchia M; Sarkar D; Fisher PB
    Expert Opin Ther Targets; 2013 Jan; 17(1):61-75. PubMed ID: 23173842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Bcl-2 for cancer therapy.
    Zhang L; Lu Z; Zhao X
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188569. PubMed ID: 34015412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemical biology of apoptosis: Revisited after 17 years.
    Yang S; Mao Y; Zhang H; Xu Y; An J; Huang Z
    Eur J Med Chem; 2019 Sep; 177():63-75. PubMed ID: 31129454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer.
    Mohammad R; Giri A; Goustin AS
    Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):20-30. PubMed ID: 18289121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
    Merino D; Lok SW; Visvader JE; Lindeman GJ
    Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy.
    Placzek WJ; Wei J; Kitada S; Zhai D; Reed JC; Pellecchia M
    Cell Death Dis; 2010 May; 1(5):e40. PubMed ID: 21364647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.
    Wang S; Yang D; Lippman ME
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):133-42. PubMed ID: 14613034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
    Yamaguchi R; Lartigue L; Perkins G
    Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of functional groups in predicting the activity of small molecule inhibitors for Bcl-2 and Bcl-xL.
    Kanakaveti V; Sakthivel R; Rayala SK; Gromiha MM
    Chem Biol Drug Des; 2017 Aug; 90(2):308-316. PubMed ID: 28112863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL-1 inhibitors - where are we now (2019)?
    Fletcher S
    Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.